Explore the 2024 trends in life sciences mergers and acquisitions, focusing on strategic shifts, challenges, and insights for future investments.

Explore insights from health insurance executives on rising healthcare costs, premiums, and legislative responses. Understand the industry's complex dynamics today.

Discover how Insilico Medicine's IPO on the Hong Kong Exchange is revolutionizing drug discovery with AI, drawing significant investor interest and market confidence.

Explore major changes in healthcare insurance for 2025, including drug pricing, Medicaid adjustments, and the role of AI in transforming risk management.

Key regulatory and legislative developments shaping U.S. healthcare and insurance in late 2025, including APTC expirations, CMS innovations, FDA initiatives, and congressional healthcare policy efforts.

Explore how high-cost gene therapies like Zolgensma are affecting U.S. employer-sponsored insurance and healthcare coverage amid rising costs and manufacturing challenges.

The U.S. federal government has paid $16 billion to Medicare Part D insurers due to rising prescription drug spending, highlighting cost and risk management challenges in Medicare drug plans.

Eli Lilly's diabetes drug Mounjaro is set to be included in China's national health insurance reimbursement list, boosting accessibility but with potential revenue impact from pricing adjustments.

Eli Lilly's Mounjaro joins China's national health insurance list for type 2 diabetes, enhancing accessibility amid pricing adjustments. Related diabetes therapies and market impacts examined.

China launches its first Commercial Health Insurance Innovative Drug List with CAR-T therapies, advancing access to innovative cancer and rare disease treatments under commercial insurance.